Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.53 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.52 |
| ▸ | FAAH | O00519 | 2/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.48 |
| ▸ | DAGLA | Q9Y4D2 | 2/20 | 0.46 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.45 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.45 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.45 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1421946 | 0.88 | PPARG (0.61) | FFAR1PTGDR2FAAHPPARGPPARA | |
| SCHEMBL415441 | 0.85 | FFAR1 (0.68) | FFAR1PTGDR2FAAHSRD5A2NR3C1 | |
| SCHEMBL29857418 | 0.85 | FFAR1 (0.59) | FFAR1FAAHFDFT1SRD5A2 | |
| SCHEMBL5725036 | 0.84 | DAGLA (0.53) | FFAR1PTGDR2DAGLA | |
| SCHEMBL4440017 | 0.84 | PTGDR2 (0.52) | FFAR1PTGDR2PPARGPPARA | |
| Hydrochloric Acid SCHEMBL8694026 | 0.83 | FFAR1 (0.67) | FFAR1PTGDR2FAAHSRD5A2NR3C1 | |
| SCHEMBL4433185 | 0.82 | PTGDR2 (0.51) | FFAR1PTGDR2PPARGPPARADAGLA | |
| Methane SCHEMBL27637860 | 0.82 | FFAR1 (0.65) | FFAR1PTGDR2FAAHSRD5A2NR3C1 | |
| SCHEMBL8784786 | 0.79 | CTBP2 (0.60) | FFAR1PTGDR2FAAHMRGPRX4 | |
| SCHEMBL4904635 | 0.79 | KMO (0.49) | FFAR1PTGDR2FAAHDAGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080021085-A1 | METHOD OF REDUCING ABETA42 AND TREATING DISEASES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2008-01-24 | — | — | US | disclosed |
| US-20080021085-A1 | METHOD OF REDUCING ABETA42 AND TREATING DISEASES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021085-A1 | METHOD OF REDUCING ABETA42 AND TREATING DISEASES | BACE1, BACE2, APP | FFAR1 3597/4885PTGDR2 3177/4885FAAH 999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.